Atay Oguzhan sold $2.7M of BLLN

Atay Oguzhan (Chairman and CEO) sold 25,001 shares of BillionToOne, Inc. (BLLN) at an average of $109.24 ($107.31–$112.44, $2.73M total) across 12 trades on 2026-11-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Atay Oguzhan
Published Nov 5, 2026, 1:42 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 2:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BLLN
Bearish
medium confidence
Mentioned
$BLLN
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNBearishLow
01

Why it matters

The market may react negatively to the loss of insider ownership, especially in a micro‑cap where insider holdings are closely watched.

02

Market read

Primary insider sale disclosure; short‑term price impact possible.

03

What to watch

Potential upcoming financing or strategic moves not disclosed; the sale could free up shares for future transactions.

Relevance 5/10Novelty 5/10Timing: after‑hours on 2026‑11‑02

Background

Form 4 filings provide the first public disclosure of insider transactions. This filing reveals the CEO fully exited his position.

Company-level read

Ticker impact

$BLLNBearishMedium confidence
Context

Chairman and CEO Atay Oguzhan sold 25,001 shares for $2.73M via a 10b5‑1 plan, reducing his stake to zero.

Expected impact

likely downward pressure as the market prices the insider divestment

Evidence & confidence

A $2.7M sale by the CEO is material for a micro‑cap and often triggers short‑term selling, though the transaction was pre‑arranged.

Market effects

Minimal; the sale is company‑specific and does not affect the broader biotech sector.

None; the filing is a US SEC disclosure with no regional macro implications.

Low; only relevant to investors in BLLN.

Counterpoint

The sale was pre‑arranged under a 10b5‑1 plan, so it may not reflect a change in outlook; investors could view it as neutral.

Key entities

  • BillionToOne, Inc.

    Biotech firm listed on NASDAQ under ticker BLLN.

  • Atay Oguzhan

    Chairman and CEO of BillionToOne, Inc.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Why is BillionToOne stock sliding today?

BillionToOne stock fell 6.2% in pre-market trading after Fuzzy Panda Research disclosed a short position and alleged regulatory and billing misconduct, including overbilling and potential unlawful practices. The company's stock had already declined from its 52-week high of $150.44, and broader market pressures contributed to the decline.

$BLLNMed

BillionToOne shares slide in pre-market trading following short-seller report

BillionToOne (BLLN) shares fell 6% premarket after a short-seller report alleged improper billing, undisclosed regulatory scrutiny, and clinical claim weaknesses. Fuzzy Panda Research, which holds a short position, cited FOIA records, anonymous sources, and billing data. The report claims potential EBITDA reduction of 80% and False Claims Act penalties up to $1.2B. BillionToOne has not responded.

$BLLNMed

BillionToOne: Q3 Earnings Snapshot

BillionToOne (BLLN) reported Q3 earnings of $17.4M, or 32 cents per share, beating estimates of 16 cents. Revenue was $123M, exceeding forecasts of $116.2M. The company expects full-year revenue between $460M and $470M. Shares have risen 39% YTD.